MLN8237 Alisertib cas 1028486-01-2

Alisertib, also known as MLN8237, is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.

Properties:

Density: 1.438 g/cm3

Boiling Point: 729.134ºC at 760 mmHg

Flash Point: 394.766ºC

Related Products:

SRT1720 hcl; Barasertib; ABT-751; MK-5108; SNS-314; SNS-314 mesylate; Abexinostat; Romidepsin; R547; Tubastatin A HCL; SCH900776; PF00477736; GW7647; Dalcetrapib

[1]. Güllü G, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood June 24, 2010 vol. 115 no. 25 5202-5213

[2]. Sloane DA, et al. Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237 ACS Chem. Biol., 2010, 5 (6), pp 563-576